Miguel Román-Rodríguez
Research Subjects
Miguel Román-Rodríguez has a total of 466 co-authors. Here are the top co-authors by number of shared publications:
- Job Frank Martien van Boven
Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
5 shared publications - David Price
Observational and Pragmatic Research Institute Singapore Singapore
4 shared publications Michelle Warner
Jean Orlow
4 shared publications- Marc Miravitlles
Department of Pneumology, Vall d’Hebron Hospital Universitari/Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
3 shared publications - Sinthia Bosnic-Anticevich
Quality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, Macquarie Park, NSW 2113, Australia; Macquarie University, Macquarie Park, NSW 2113, Australia
3 shared publications - Alberto Papi
University of Ferrara, S. Anna University Hospital, Ferrara, Italy
2 shared publications
Latest Publications
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 19, 1583-1591
Treatment decisions: insights from people with asthma or COPD and their healthcare providers on disease and treatment decisions
Treatment decisions: insights from people with asthma or COPD and their healthcare providers on disease and treatment decisions
- 1 June 2025
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 19, 1583-1591
Open AccessTreatment decisions: insights from people with asthma or COPD and their healthcare providers on disease and treatment decisions
Treatment decisions: insights from people with asthma or COPD and their healthcare providers on disease and treatment decisions
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 18, 2295-2306
Perspectives on Treatment Decisions, Preferences, and Adherence and Long-Term Management in Asthma and COPD: A Qualitative Analysis of Patient, Caregiver, and Healthcare Provider Insights
Purpose: Asthma and chronic obstructive pulmonary disease (COPD) are associated with substantial morbidity and mortality. This analysis assessed patient, caregiver, and healthcare provider (HCP) opinions regarding asthma and COPD diagnosis and treatment, including inhaler device preferences. Patients and Methods: Insights were from: (1) face-to-face/telephone patient/HCP communications with GSK Global Medical Teams; (2) social media listening; (3) a self-completed online patient/caregiver survey. Data were anonymized and informed consent was provided. Qualitative outputs were extracted, analyzed inductively, and coded per key themes, such as treatment preferences (including perceptions of single inhaler triple therapy [SITT] versus multiple inhaler triple therapy [MITT]) and long-term treatment goals. Data could be assigned to ≥ 1 theme. Results: Overall, 2966 patient and HCP insights (patients, 1150; HCPs, 1816), 988 social media posts, and 44 survey responses (patients, 33; caregivers, 11) were included. Within this analysis, some patients delayed seeking medical advice due to lack of disease understanding and used alternative information sources to better understand treatment options (eg, social media). Patients preferred SITT over MITT in terms of convenience, ease of use, and perceived efficacy; some believed that MITT provided greater coverage due to frequent dosing. HCPs recognized the tendency of patient preferences to drive treatment decisions, and highlighted a reluctance to change therapy among some patients, particularly those well controlled in current therapy. Patients preferred therapies with a shorter onset of action. Patients tended to measure treatment success by symptom improvement and quality of life, whereas HCPs measured treatment success through clinical tests. HCPs reported a lack of patient awareness of the mortality risk associated with COPD. Conclusion: There is discordance between patient and HCP perceptions of treatment success and goals in asthma and COPD. Improved patient education and HCP-patient communication are needed to facilitate meaningful shared decision-making, optimize care plans, and provide early treatment options.
- 1 November 2024
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 18, 2295-2306
Open AccessPerspectives on Treatment Decisions, Preferences, and Adherence and Long-Term Management in Asthma and COPD: A Qualitative Analysis of Patient, Caregiver, and Healthcare Provider Insights
Purpose: Asthma and chronic obstructive pulmonary disease (COPD) are associated with substantial morbidity and mortality. This analysis assessed patient, caregiver, and healthcare provider (HCP) opinions regarding asthma and COPD diagnosis and treatment, including inhaler device preferences. Patients and Methods: Insights were from: (1) face-to-face/telephone patient/HCP communications with GSK Global Medical Teams; (2) social media listening; (3) a self-completed online patient/caregiver survey. Data were anonymized and informed consent was provided. Qualitative outputs were extracted, analyzed inductively, and coded per key themes, such as treatment preferences (including perceptions of single inhaler triple therapy [SITT] versus multiple inhaler triple therapy [MITT]) and long-term treatment goals. Data could be assigned to ≥ 1 theme. Results: Overall, 2966 patient and HCP insights (patients, 1150; HCPs, 1816), 988 social media posts, and 44 survey responses (patients, 33; caregivers, 11) were included. Within this analysis, some patients delayed seeking medical advice due to lack of disease understanding and used alternative information sources to better understand treatment options (eg, social media). Patients preferred SITT over MITT in terms of convenience, ease of use, and perceived efficacy; some believed that MITT provided greater coverage due to frequent dosing. HCPs recognized the tendency of patient preferences to drive treatment decisions, and highlighted a reluctance to change therapy among some patients, particularly those well controlled in current therapy. Patients preferred therapies with a shorter onset of action. Patients tended to measure treatment success by symptom improvement and quality of life, whereas HCPs measured treatment success through clinical tests. HCPs reported a lack of patient awareness of the mortality risk associated with COPD. Conclusion: There is discordance between patient and HCP perceptions of treatment success and goals in asthma and COPD. Improved patient education and HCP-patient communication are needed to facilitate meaningful shared decision-making, optimize care plans, and provide early treatment options.
- Open Access
- 31 October 2023
- Published by Associacao Portuguesa de Medicina Geral e Familiar in Revista Portuguesa de Clínica Geral
- Vol. 39 (5) , 184-185
Drug or inhaler… Which is first?
- 31 October 2023
- Published by Associacao Portuguesa de Medicina Geral e Familiar in Revista Portuguesa de Clínica Geral
- Vol. 39 (5) , 184-185
Open AccessDrug or inhaler… Which is first?
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA543
Early treatment intervention and long-term management in COPD: a patient-focused analysis
Background: Symptoms of COPD can impact upon a patient’s QoL. Diagnosis is often delayed following onset of symptoms. Aim: This patient-focused analysis aims to understand the impact of delayed treatment and benefits of early intervention for optimal management of COPD. Methods: Qualitative patient and provider insight data were collected from three sources in 2021: interactions between HCPs and GSK; social media platforms (specialist and non-specialist); and an independent online patient survey. A content analysis method was used to anonymise, collate data across all sources, and categorise using key words to identify common themes. Results: HCP interactions constituted 2966 entries (1816 HCPs) and provided HCP-reported insights. Social media data came from 988 posts (a subset of which [n=153] included 97% patients, aged 41–<81 years, 75% female). Forty-four participants completed the patient survey (33 patients with mild-moderate COPD, 11 caregivers); 66% female, aged 20–69 years). Patient/HCP reports on challenges to diagnosis, long-term treatment and effective patient-HCP communication are detailed in the Table. Early diagnosis was associated with greater QoL vs delayed diagnosis. Conclusions: There is a need for early diagnosis and effective patient-HCP communication throughout treatment including a continued open and active patient-HCP dialogue to improve COPD management and QoL. Funding: GSK-sponsored study
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA543
Early treatment intervention and long-term management in COPD: a patient-focused analysis
Background: Symptoms of COPD can impact upon a patient’s QoL. Diagnosis is often delayed following onset of symptoms. Aim: This patient-focused analysis aims to understand the impact of delayed treatment and benefits of early intervention for optimal management of COPD. Methods: Qualitative patient and provider insight data were collected from three sources in 2021: interactions between HCPs and GSK; social media platforms (specialist and non-specialist); and an independent online patient survey. A content analysis method was used to anonymise, collate data across all sources, and categorise using key words to identify common themes. Results: HCP interactions constituted 2966 entries (1816 HCPs) and provided HCP-reported insights. Social media data came from 988 posts (a subset of which [n=153] included 97% patients, aged 41–<81 years, 75% female). Forty-four participants completed the patient survey (33 patients with mild-moderate COPD, 11 caregivers); 66% female, aged 20–69 years). Patient/HCP reports on challenges to diagnosis, long-term treatment and effective patient-HCP communication are detailed in the Table. Early diagnosis was associated with greater QoL vs delayed diagnosis. Conclusions: There is a need for early diagnosis and effective patient-HCP communication throughout treatment including a continued open and active patient-HCP dialogue to improve COPD management and QoL. Funding: GSK-sponsored study
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA542
Patient perspectives on treatment preference and adherence to treatment for chronic obstructive pulmonary disease
Background: Prescription medication is the primary approach to COPD management, alongside lifestyle changes. Aim: To assess patient views on treatment preference and adherence to optimise COPD management. Methods: Qualitative patient and provider insight data were collected from three sources in 2021: interactions between HCPs and GSK; social media sites (specialist and non-specialist); and an independent online patient survey. A content analysis method was used to anonymise, collate and categorise data using key words to identify common themes. Results: HCP interactions constituted 2966 entries and provided HCP-reported patient insights. Social media data included 988 posts (a subset of which [n=153] included 97% patients, aged 41–<81 years). Forty-four survey respondents included 33 patients (mild-moderate COPD) and 11 caregivers aged 20–69 years. Based on insights from HCP/GSK interactions and social media, patients lacked disease and treatment option understanding, highlighting the need for improved patient education (Table). For treatment preference, patients reported one dose (triple therapy) is more convenient than several different inhaled therapies, and may increase likelihood of greater adherence (Table). Conclusions: This analysis revealed common themes around patient treatment preference and adherence including suboptimal disease understanding and device/dosage education. Funding: GSK-sponsored study
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA542
Patient perspectives on treatment preference and adherence to treatment for chronic obstructive pulmonary disease
Background: Prescription medication is the primary approach to COPD management, alongside lifestyle changes. Aim: To assess patient views on treatment preference and adherence to optimise COPD management. Methods: Qualitative patient and provider insight data were collected from three sources in 2021: interactions between HCPs and GSK; social media sites (specialist and non-specialist); and an independent online patient survey. A content analysis method was used to anonymise, collate and categorise data using key words to identify common themes. Results: HCP interactions constituted 2966 entries and provided HCP-reported patient insights. Social media data included 988 posts (a subset of which [n=153] included 97% patients, aged 41–<81 years). Forty-four survey respondents included 33 patients (mild-moderate COPD) and 11 caregivers aged 20–69 years. Based on insights from HCP/GSK interactions and social media, patients lacked disease and treatment option understanding, highlighting the need for improved patient education (Table). For treatment preference, patients reported one dose (triple therapy) is more convenient than several different inhaled therapies, and may increase likelihood of greater adherence (Table). Conclusions: This analysis revealed common themes around patient treatment preference and adherence including suboptimal disease understanding and device/dosage education. Funding: GSK-sponsored study
- Open Access
- 25 September 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 2401-2415
Suboptimal Peak Inspiratory Flow and Critical Inhalation Errors are Associated with Higher COPD-Related Healthcare Costs
Purpose: To assess the relationship between suboptimal Peak Inspiratory Flow (sPIF), inhalation technique errors, and non-adherence, with Healthcare Resource Utilisation (HCRU) in Chronic Obstructive Pulmonary Disease (COPD) patients receiving maintenance therapy via a Dry Powder Inhaler (DPI). Patients and methods: The cross-sectional, multi-country PIFotal study included 1434 COPD patients (≥ 40 years) using a DPI for maintenance therapy. PIF was measured with the In-Check DIAL G16, and sPIF was defined as a typical PIF lower than required for the device. Inhalation technique was assessed by standardised evaluation of video recordings and grouped into 10 steps. Patients completed the “Test of Adherence to Inhalers” questionnaire. HCRU was operationalised as COPD-related costs for primary healthcare, secondary healthcare, medication, and total COPD-related costs in a 1-year period. Results: Participants with sPIF had higher medication costs compared with those with optimal PIF (cost ratio [CR]: 1.07, 95% CI [1.01, 1.14]). Multiple inhalation technique errors were associated with increased HCRU. Specifically, “insufficient inspiratory effort” with higher secondary healthcare costs (CR: 2.20, 95% CI [1.37, 3.54]) and higher total COPD-related costs (CR: 1.16, 95% CI 1.03– 1.31). “no breath-hold following the inhalation manoeuvre (< 6 s)” with higher medication costs (CR: 1.08, 95% CI [1.02, 1.15]) and total COPD-related costs (CR 1.17, 95% CI [1.07, 1.28]), and “not breathing out calmly after inhalation” with higher medication costs (CR: 1.19, 95% CI [1.04, 1.37]). Non-adherence was not significantly associated with HCRU. Conclusion: sPIF and inhalation technique errors were associated with higher COPD-related healthcare utilisation and costs in COPD patients on DPI maintenance therapy.
- 25 September 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 2401-2415
Open AccessSuboptimal Peak Inspiratory Flow and Critical Inhalation Errors are Associated with Higher COPD-Related Healthcare Costs
Purpose: To assess the relationship between suboptimal Peak Inspiratory Flow (sPIF), inhalation technique errors, and non-adherence, with Healthcare Resource Utilisation (HCRU) in Chronic Obstructive Pulmonary Disease (COPD) patients receiving maintenance therapy via a Dry Powder Inhaler (DPI). Patients and methods: The cross-sectional, multi-country PIFotal study included 1434 COPD patients (≥ 40 years) using a DPI for maintenance therapy. PIF was measured with the In-Check DIAL G16, and sPIF was defined as a typical PIF lower than required for the device. Inhalation technique was assessed by standardised evaluation of video recordings and grouped into 10 steps. Patients completed the “Test of Adherence to Inhalers” questionnaire. HCRU was operationalised as COPD-related costs for primary healthcare, secondary healthcare, medication, and total COPD-related costs in a 1-year period. Results: Participants with sPIF had higher medication costs compared with those with optimal PIF (cost ratio [CR]: 1.07, 95% CI [1.01, 1.14]). Multiple inhalation technique errors were associated with increased HCRU. Specifically, “insufficient inspiratory effort” with higher secondary healthcare costs (CR: 2.20, 95% CI [1.37, 3.54]) and higher total COPD-related costs (CR: 1.16, 95% CI 1.03– 1.31). “no breath-hold following the inhalation manoeuvre (< 6 s)” with higher medication costs (CR: 1.08, 95% CI [1.02, 1.15]) and total COPD-related costs (CR 1.17, 95% CI [1.07, 1.28]), and “not breathing out calmly after inhalation” with higher medication costs (CR: 1.19, 95% CI [1.04, 1.37]). Non-adherence was not significantly associated with HCRU. Conclusion: sPIF and inhalation technique errors were associated with higher COPD-related healthcare utilisation and costs in COPD patients on DPI maintenance therapy.
- Open Access
- 1 January 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 245-258
Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
Purpose: Inhaled corticosteroids (ICS) are frequently used to treat chronic obstructive pulmonary disease (COPD) outside the current recommendations. Our aim was to describe ICS use in COPD patients and to identify factors associated with ICS use among COPD patients treated within primary care in Spain. Patients and Methods: This was a cross-sectional, non-interventional and multicenter study of patients with COPD treated in primary care. Patient characteristics and exacerbations were described in terms of ICS use among the overall cohort, and among those with spirometry confirmed COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] ratio < 70%). Multivariable logistic regression was used to identify factors associated with ICS use. Results: A total of 901 patients were included, of which 47.9% (n = 432) were treated with ICS. A total of 240 patients (26.6%) experienced moderate/severe exacerbations in the prior year, while 309 (34.3%) during the previous two years. History of asthma totaled 11.6% (n = 105). The most frequent phenotype was non-exacerbator (51.6%), and the proportion of patient with moderate or severe exacerbations was significantly higher among ICS treated patients compared to non-treated: 37.5% versus 16.6% during the previous year (p < 0.001), and 46.8% versus 22.8% during the previous 2-years (p < 0.001), respectively. Patient characteristics were similar among spirometry confirmed patients and the overall population. Factors significantly associated with ICS use were a history of asthma (OR = 4.39, 95% CI: 2.67– 7.26), the presence of moderate or severe exacerbations in the last year (OR = 2.52, 95% CI: 1.81– 3.49), followed by higher mMRC and higher CAT score. Conclusion: Nearly half of patients in primary care in Spain are treated with ICS, despite most of them being non-exacerbators. History of asthma, exacerbations, and worse dyspnea and CAT scores are associated with ICS use.
- 1 January 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 245-258
Open AccessInhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
Purpose: Inhaled corticosteroids (ICS) are frequently used to treat chronic obstructive pulmonary disease (COPD) outside the current recommendations. Our aim was to describe ICS use in COPD patients and to identify factors associated with ICS use among COPD patients treated within primary care in Spain. Patients and Methods: This was a cross-sectional, non-interventional and multicenter study of patients with COPD treated in primary care. Patient characteristics and exacerbations were described in terms of ICS use among the overall cohort, and among those with spirometry confirmed COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] ratio < 70%). Multivariable logistic regression was used to identify factors associated with ICS use. Results: A total of 901 patients were included, of which 47.9% (n = 432) were treated with ICS. A total of 240 patients (26.6%) experienced moderate/severe exacerbations in the prior year, while 309 (34.3%) during the previous two years. History of asthma totaled 11.6% (n = 105). The most frequent phenotype was non-exacerbator (51.6%), and the proportion of patient with moderate or severe exacerbations was significantly higher among ICS treated patients compared to non-treated: 37.5% versus 16.6% during the previous year (p < 0.001), and 46.8% versus 22.8% during the previous 2-years (p < 0.001), respectively. Patient characteristics were similar among spirometry confirmed patients and the overall population. Factors significantly associated with ICS use were a history of asthma (OR = 4.39, 95% CI: 2.67– 7.26), the presence of moderate or severe exacerbations in the last year (OR = 2.52, 95% CI: 1.81– 3.49), followed by higher mMRC and higher CAT score. Conclusion: Nearly half of patients in primary care in Spain are treated with ICS, despite most of them being non-exacerbators. History of asthma, exacerbations, and worse dyspnea and CAT scores are associated with ICS use.
- Open Access
- 9 September 2021
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 31 (1) , 1-7
Targeting exertional breathlessness to improve physical activity: the role of primary care
Primary care physicians (PCPs) play a crucial role in the diagnosis and management of chronic obstructive pulmonary disease (COPD). By working together with patients to target exertional breathlessness and increase physical activity, PCPs have an important role to play, early in the disease course, in improving patient outcomes in both the short and long term. In this article, we consider how physical activity affects disease progression from the PCP perspective. We discuss the role of pharmacological therapy, the importance of an holistic approach and the role of PCPs in assessing and promoting physical activity. The complexity and heterogeneity of COPD make it a challenging disease to treat. Patients’ avoidance of activity, and subsequent decline in capacity to perform it, further impacts the management of the disease. Improving patient tolerance of physical activity, increasing participation in daily activities and helping patients to remain active are clear goals of COPD management. These may require an holistic approach to management, including pulmonary rehabilitation and psychological programmes in parallel with bronchodilation therapy, in order to address both physiological and behavioural factors. PCPs have an important role to optimise therapy, set goals and communicate the importance of maintaining physical activity to their patients. In addition, optimal treatment that addresses activity-related breathlessness can help prevent the downward spiral of inactivity and get patients moving again, to improve their overall health and long-term prognosis.
- 9 September 2021
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 31 (1) , 1-7
Open AccessTargeting exertional breathlessness to improve physical activity: the role of primary care
Primary care physicians (PCPs) play a crucial role in the diagnosis and management of chronic obstructive pulmonary disease (COPD). By working together with patients to target exertional breathlessness and increase physical activity, PCPs have an important role to play, early in the disease course, in improving patient outcomes in both the short and long term. In this article, we consider how physical activity affects disease progression from the PCP perspective. We discuss the role of pharmacological therapy, the importance of an holistic approach and the role of PCPs in assessing and promoting physical activity. The complexity and heterogeneity of COPD make it a challenging disease to treat. Patients’ avoidance of activity, and subsequent decline in capacity to perform it, further impacts the management of the disease. Improving patient tolerance of physical activity, increasing participation in daily activities and helping patients to remain active are clear goals of COPD management. These may require an holistic approach to management, including pulmonary rehabilitation and psychological programmes in parallel with bronchodilation therapy, in order to address both physiological and behavioural factors. PCPs have an important role to optimise therapy, set goals and communicate the importance of maintaining physical activity to their patients. In addition, optimal treatment that addresses activity-related breathlessness can help prevent the downward spiral of inactivity and get patients moving again, to improve their overall health and long-term prognosis.
- Open Access
- 1 June 2021
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 1709-1715
GOLD 2021 Strategy Report: Implications for Asthma–COPD Overlap
In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease states: “we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that asthma and COPD are different disorders, although they may […] coexist in an individual patient. If a concurrent diagnosis of asthma is suspected, pharmacotherapy should primarily follow asthma guidelines, but pharmacological and non-pharmacological approaches may also be needed for their COPD.” What does this mean for the treating physician? In this review, we explore the implications of this new guidance on treating patients with chronic obstructive pulmonary disease, arguing for a personalized approach to treatment.
- 1 June 2021
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 1709-1715
Open AccessGOLD 2021 Strategy Report: Implications for Asthma–COPD Overlap
In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease states: “we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that asthma and COPD are different disorders, although they may […] coexist in an individual patient. If a concurrent diagnosis of asthma is suspected, pharmacotherapy should primarily follow asthma guidelines, but pharmacological and non-pharmacological approaches may also be needed for their COPD.” What does this mean for the treating physician? In this review, we explore the implications of this new guidance on treating patients with chronic obstructive pulmonary disease, arguing for a personalized approach to treatment.
- 1 April 2021
- Published by Elsevier in Revista Clínica Española (English Edition)
- Vol. 221 (4) , 207-216
Compliance with the clinical guidelines for managing asthma by primary care physicians: An ambispective observational study
- 1 April 2021
- Published by Elsevier in Revista Clínica Española (English Edition)
- Vol. 221 (4) , 207-216
Compliance with the clinical guidelines for managing asthma by primary care physicians: An ambispective observational study